Fig. 1 · Structure

Documents & Downloads

Aztreonam

Cat. No. A10118 CAS 78110-38-0
Aztreonam is a synthetic monocyclic beta-lactam antibiotic (a monobactam), with the nucleus based on a simpler monobactam isolated from Chromobacterium violaceum.

In Stock

Publications for Aztreonam

3 publications citing this product

  1. Sreevalli Sharma, .et al. , ACS Infect Dis, 2021, Nov 12;7(11):3009-3024 PMID: 34699190
  2. Pholwat S, .et al. , PLoS One, 2019, May 10;14(5):e0216747 PMID: 31075137
  3. Robert Bucki, .et al. , Infect Drug Resist, 2018, 11: 77-86 PMID: 29391814

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Aztreonam forms a covalent acyl complex with purified Pseudomonas aeruginosa PBP3, supporting PBP3 as a molecular target. This structural experiment does not establish whole-cell antibacterial potency. [1]

In a purified E. coli PBP1b competition assay, aztreonam gave an IC50 of 98.5 ± 6.0 µM, compared with 9.0 ± 0.6 µM for benzyl-penicillin (SD; three technical replicates). These assay-specific findings show that strong PBP3 binding should not be generalized to all penicillin-binding proteins. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
β-lactam  

In Vitro Studies

Aztreonam–PBP3 acyl-complex structure

Biochemical assay · Purified soluble Pseudomonas aeruginosa PBP3, residues 50–579, N-terminal His6 tag [1]

The original structure shows ring-opened aztreonam covalently associated with the PBP3 active-site serine. Apo PBP3 and other β-lactam complexes provide structural comparators; this experiment does not measure bacterial growth inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Formation of an aztreonam-acyl-PBP3 complexStructural observation Observed[1]

Literature-Reported Treatment Conditions

Method
Aztreonam was soaked into crystals of purified PBP3.
Reported limits
Exact soaking concentration/time and compound supplier, batch purity and salt characterization are not established by the acquired main text; SI was not retrieved.
Methods and source locations

Compound reported in the paper: Aztreonam

Supports a molecular target-binding mechanism for aztreonam, without validating a catalog lot or predicting cellular efficacy.

Results: The Efficient Binding of Monobactam Aztreonam to PaPBP3; Fig. 3A; Fig. 1B; Experimental Procedures: construct, crystallization and structure determination

Formation of an aztreonam-acyl-PBP3 complex: X-ray crystallography of aztreonam-soaked PBP3 crystals; apo and other ligand-bound structures compared — Fig. 3A and aztreonam-binding Results section

Weaker aztreonam competition at E. coli PBP1b

Biochemical assay · Purified Escherichia coli PBP1b; gel-based BOCILLIN FL competition assay [2]

Aztreonam reduced residual BOCILLIN FL binding with a reported IC50 of 98.5 ± 6.0 µM. Benzyl-penicillin gave 9.0 ± 0.6 µM in the same assay; cephalexin and kanamycin showed no inhibition up to 1000 µM. These are assay-specific competition endpoints, not a cellular potency ranking.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% reduction of residual BOCILLIN FL binding to PBP1bIC50 98.5 ± 6.0 µM[2]
Benzyl-penicillin competition in the same purified PBP1b assayIC50 9.0 ± 0.6 µM[2]
Cephalexin and kanamycin competition controlsReported inhibition limit No inhibition up to 1000 µM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Aztreonam concentration-response series; 25 µM BOCILLIN FL and 13 µM purified PBP1b
Exposure duration
30 min at 25 °C
Method
Simultaneous addition of unlabeled compound and reporter; SDS-PAGE separation and ImageJ fluorescence densitometry.
Vehicle
Reaction buffer: 20 mM Tris pH 8.0, 300 mM NaCl, 4.5 mM DM.
Co-treatment
Bocillin FL is a reporter; comparator compounds were assessed separately.
Reported limits
Aztreonam supplier, lot purity and stock solvent are not established in the read material.
Methods and source locations

Compound reported in the paper: Aztreonam

Demonstrates relatively weak competition at E. coli PBP1b in this assay. No numerical cross-paper selectivity ratio is inferred.

Fig. 7D and caption; aztreonam Results paragraph; Experimental Procedures: gel-based BOCILLIN FL competition paragraph

50% reduction of residual BOCILLIN FL binding to PBP1b: Gel fluorescence densitometry; reported variability is SD from three separate technical replicates; normalized to reporter labeling without unlabeled competitor — Fig. 7D, printed legend and caption; competition Experimental Procedures

Benzyl-penicillin competition in the same purified PBP1b assay: Same gel-based competition assay; SD, three technical replicates — Fig. 7D and accompanying Results text

Cephalexin and kanamycin competition controls: NI definition in Fig. 7 caption; observed flat comparator responses viewed — Fig. 7D and caption

In Vivo Studies

In four beagles given a single intravenous 25 mg/kg dose of radiolabeled aztreonam in an L-arginine-containing aqueous formulation, 85.2 ± 1.63% of the radioactive dose appeared in urine over 0–24 h. Unchanged aztreonam represented 86.1 ± 1.1% of that urinary radioactivity (mean ± SEM). This is a formulation-specific disposition result. [3]

Urinary disposition of radiolabeled aztreonam in dogs

Animal study · Four male beagles receiving radiolabeled aztreonam with L-arginine [3]

Following a single intravenous dose, most recovered urinary radioactivity during 0–24 h was unchanged aztreonam. The ring-opened metabolite SQ 26,992 contributed 10.0 ± 0.5% of urinary radioactivity. The results describe disposition of the study formulation rather than antibacterial efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total urinary radioactive recovery at 0–24 hPercent of administered radioactive dose 85.2 ± 1.63%[3]
Unchanged aztreonam fraction of urinary radioactivityRelative percent in urine 86.1 ± 1.1%[3]
Ring-opened metabolite SQ 26,992 fraction of urinary radioactivityRelative percent in urine 10.0 ± 0.5%[3]

Conditions shared by the study groups

Route
Intravenous
Frequency
Single administration
Treatment course
Urine outcome interval 0–24 h; broader excretion follow-up to 96 h
Vehicle
Labeled and unlabeled aztreonam dissolved in water with an equimolar amount of L-arginine
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Single intravenous 25 mg/kg dose
25 mg/kg [14C]aztreonam as reported
Predose control matrices spiked for stability/recovery; chromatographic separation of parent and metabolites; no untreated efficacy armAt 0–24 h, total urinary radioactivity was 85.2 ± 1.63% of dose; unchanged aztreonam accounted for 86.1 ± 1.1% of that urinary radioactivity.[3]
Single intravenous 25 mg/kg dose
Model: Four young adult male purebred beagles, 9–11 kg
Reported limits: No conversion to free-acid dose or extrapolation to catalog material; SEM values and n = 4 retained as reported.
Methods and source locations

Compound reported in the paper: Aztreonam

Animal disposition of the explicitly reported radiolabeled arginine-containing formulation only; no claim for free-acid formulation equivalence.

pp. 119–120 compound/form and dog dosing; p. 122 urine stability and statistical conventions; p. 123 Table 1 and dog biotransformation text

Total urinary radioactive recovery at 0–24 h: Liquid scintillation counting; mean ± SEM, four dogs — p. 123 Table 1, cumulative 0–24 h, intravenous columns

Unchanged aztreonam fraction of urinary radioactivity: Thin-layer radiochromatographic analysis with parent/metabolite reference compounds; mean ± SEM, four dogs — p. 123 Table 1, cumulative 0–24 h, intravenous aztreonam column

Ring-opened metabolite SQ 26,992 fraction of urinary radioactivity: Chromatographic separation; mean ± SEM, four dogs — p. 123 Table 1, cumulative 0–24 h, intravenous SQ 26,992 column

Single intravenous 25 mg/kg dose · pp. 119–120 compound/form and dog dosing; p. 122 urine stability and statistical conventions; p. 123 Table 1 and dog biotransformation text

Specifications

Manufacturer Adooq Bioscience
CAS Number 78110-38-0
Formula C13H17N5O8S2
Molecular Weight 435.4
Synonyms Monobactam; SQ 26776; Squibb 26776; Cayston; Azactam
SMILES
C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\OC(C)(C)C(=O)O)/C2=CSC(=N2)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 84 mg/mL (192.91 mM)
Water 11 mg/mL (25.26 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Han S, Zaniewski RP, Marr ES, et al. Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa. Proceedings of the National Academy of Sciences of the United States of America (2010). PMID: 21135211 DOI: 10.1073/pnas.1013092107 Source material
  2. [2] King DT, Wasney GA, Nosella M, et al. Structural Insights into Inhibition of Escherichia coli Penicillin-binding Protein 1B. The Journal of biological chemistry (2017). PMID: 27899450 DOI: 10.1074/jbc.m116.718403 Source material
  3. [3] Kripalani KJ, Singhvi SM, Weinstein SH, et al. Disposition of [14C]aztreonam in rats, dogs, and monkeys. Antimicrobial agents and chemotherapy (1984). PMID: 6541449 DOI: 10.1128/aac.26.2.119 Source material

Publications

3 publications citing this product

  1. Sreevalli Sharma, .et al. , ACS Infect Dis, 2021, Nov 12;7(11):3009-3024 PMID: 34699190
  2. Pholwat S, .et al. , PLoS One, 2019, May 10;14(5):e0216747 PMID: 31075137
  3. Robert Bucki, .et al. , Infect Drug Resist, 2018, 11: 77-86 PMID: 29391814

Added to your cart

View Cart Checkout
Loading...